Characteristics and incidence of vaccine adverse events after Bacille Calmette-Guerin vaccination: A national surveillance study in Japan from 2013 to 2017.
BACKGROUND: Japan amended the recommended age for the Bacille Calmette-Guerin (BCG) vaccination to less than 6 months after 2005, but subsequently amended the recommended age to 5-8 months (latest amendment, <1 year) in April 2013 due to the increasing incidence of BCG-associated osteitis/osteomyelitis since 2005.
METHODS: We collected data on BCG-associated vaccine adverse events (VAEs) in the population aged <1 year between April 2013 and March 2017. The incidence of BCG-associated VAE was analyzed using census and vaccine coverage data from the government website. We compared the incidence of VAEs in patients vaccinated at less than 6 months with those vaccinated at 6 months or older.
RESULTS: Among the 581 BCG-associated VAEs recorded during the study period, 354 (61%) were male, and the average age at vaccination was 5.7 months. The incidence of VAEs per million population aged <1 year at vaccination was highest for suppurative lymphadenitis (63.7), followed by skin lesions (38.4), and BCG-associated osteitis/osteomyelitis (3.1). Disseminated BCG and anaphylaxis were rare (1.1 and 1.6%, respectively). The incidence of VAEs in the population vaccinated at <6 months of age was higher for BCG-associated osteitis/osteomyelitis (3.8) and disseminated BCG (1.3) than in the population vaccinated at >/=6 months.
CONCLUSIONS: The population vaccinated at <6 months of age was more likely to develop BCG-associated osteitis/osteomyelitis than the population vaccinated at >/=6 months of age, indicating that the change in the recommended vaccination age in 2013 might have contributed to the subsequent decrease in the incidence of BCG-associated osteitis/osteomyelitis.
|投稿者||Okuno, Hideo; Satoh, Hiroshi; Morino, Saeko; Arai, Satoru; Ochiai, Masaki; Fujita, Kentaro; Naito, Seishiro; Kato, Atsushi; Ishii, Koji; Oishi, Kazunori; Suzuki, Motoi; Tanaka-Taya, Keiko|
|組織名||Center for Surveillance, Immunization, and Epidemiologic Research, National;Institute of Infectious Diseases, Tokyo, Japan; Division of Infection Control and;Prevention, Osaka University Hospital, Osaka, Japan.;Environmental Health Division, Takasaki City Health Center, Gunma, Japan.;Institute of Infectious Diseases, Tokyo, Japan.;Department of Quality Assurance and Radiological Protection, National Institute;of Infectious Diseases, Tokyo, Japan.;of Infectious Diseases, Tokyo, Japan; Nippon Institute for Biological Science,;Tokyo, Japan; Biomedical Science Association, Tokyo, Japan.;Toyama Institute of Health, Toyama, Japan.;Institute of Infectious Diseases, Tokyo, Japan. Electronic address:;firstname.lastname@example.org.|